ReviewDermatologic therapy2022
Latest combination therapies in psoriasis: Narrative review of the literature.
Review in Dermatologic therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Advanced hydrogel-based drug delivery systems for psoriasis management: From material design to multi-target therapies.International journal of pharmaceutics: X · 2026Review
- Research trends and priorities in the treatment of psoriatic arthritis from 2014 to 2024: A bibliometric and visualization study.Medicine · 2026Article
- Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study.Drugs - real world outcomes · 2025Article
- Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.Advances in therapy · 2025Review
- Hypoxia-induced RHCG as a key regulator in psoriasis and its modulation by secukinumab.APL bioengineering · 2025Article
- Apremilast Coadministered with Secukinumab for Effective Treatment of Acrodermatitis Continua of Hallopeau: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- [Variants of biotechnological drugs in dermatology : Status quo and future].Dermatologie (Heidelberg, Germany) · 2024Article
- The use of dual biologic therapy for the management of recalcitrant psoriasis.JAAD case reports · 2024Article
- Dynamic Boolean modeling of molecular and cellular interactions in psoriasis predicts drug target candidates.iScience · 2024Article
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib.Frontiers in immunology · 2024Observational
- Lipoprotein(a) is a new prognostic factor in patients with psoriasis and coronary artery disease: a retrospective cohort study.Lipids in health and disease · 2023Article
- Difficult to treat psoriatic arthritis - how should we manage?Clinical rheumatology · 2023Review
- Effects of Metabolic Syndrome on Cardiovascular Outcomes of Psoriatic Patients with Coronary Artery Disease: A Single Center Retrospective Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Latest combination therapies in psoriasis: Narrative review of the literature.Dermatologic therapy · 2022Review
- Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives.International journal of molecular sciences · 2022Review
- Dissolvable hyaluronic acid microneedles loaded with β-Elemene for the treatment of psoriasis.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always provide complete control of the disease or associated comorbidities over time. The first biological drugs used for the treatment of psoriasis, tumor necrosis factor alpha inhibitors, have long been used in combination with traditional topical and systemic therapies to induce a complete remission of the disease that could not be achieved with innovative drug alone. Even with the advent of new biological therapies with more precise molecular targets, the challenge of using combination therapies remained. Psoriatic patients often have major comorbidities, such as arthritis, inflammatory bowel disease, uveitis or have other concomitant conditions such as chronic spontaneous urticaria and atopic dermatitis, which may require different biologic treatments than those indicated in psoriasis. The objective of this article is, through a comprehensive revision of the literature, to analyze in which cases the use of the combination of the latest therapies for psoriasis may be useful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.